Life Sciences Leader Bruce Goodwin Appointed to Board
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
19 NOVEMBER 2025
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
LIFE SCIENCES LEADER BRUCE GOODWIN APPOINTED
NON-EXECUTIVE DIRECTOR
Sydney, Australia – 19 November 2025 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the
“Company”), a developer of a world‐class platform of radiopharmaceutical products for both
diagnostic and therapeutic uses, is pleased to announce the appointment of Mr Bruce Goodwin as a
Non-Executive Director, effective 19 November 2025.
Mr Goodwin is a highly respected leader in the life sciences sector, bringing over four decades of
experience across global healthcare and biopharmaceutical industries. He currently serves as a Non-
Executive Director across six organisations operating within the healthcare sector, where he
provides strategic guidance and governance expertise.
Mr Goodwin’s career includes more than three decades with the Janssen Pharmaceutical Companies
of Johnson & Johnson, during which he held senior leadership roles across multiple countries and
regions. His tenure was marked by a strong record of driving organisational growth, fostering
innovation, and leading high-performing teams in complex, multinational environments.
Mr Goodwin has demonstrated a deep commitment to advancing the life sciences industry. He has
served on industry peak body boards in Australia and Japan, contributing to policy development,
regulatory dialogue, and cross-sector collaboration. He is also regarded for his strategic acumen,
global perspective, and passion for improving health outcomes through innovation, leadership, and
effective governance.
In conjunction with this appointment, Radiopharm advises that Mr Phillip Hains and Dr Leila Alland
will retire from the Board at the 2025 Annual General Meeting this month. Mr Hains will continue in
his current roles as Chief Financial Officer and Company Secretary following his retirement from the
Board.
Radiopharm Executive Chairman Paul Hopper said:
“We are delighted to welcome Bruce to the Radiopharm Board. His exceptional leadership
experience, particularly his long tenure with Johnson & Johnson and deep understanding of the
biopharmaceutical landscape, will be invaluable as we continue to advance our pipeline and
strengthen our global profile.
On behalf of the Board, I would also like to thank Phillip and Leila for their contributions to
Radiopharm’s growth and governance since listing. We look forward to continuing to work closely
with Phillip in his executive capacities and with Leila as a consultant to the Medical Team of
Radiopharm.”
ASX ANNOUNCEMENT
19 NOVEMBER 2025
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class
platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in
areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The
company has a pipeline of distinct and highly differentiated platform technologies spanning
peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes
one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and
brain metastases. Learn more at radiopharmtheranostics.com.
Authorised on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman
Paul Hopper.
For more information:
Investors:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Anne Marie Fields
Precision AQ
(Formerly Stern IR)
E: annemarie.fields@precisionaq.com
Media:
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Linked In – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
Share your feedback
Discover